Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- POLA +25.9%, MVIS +17.9%
M&A news:
- CNCE +33.7% (to sell CTP-656 to Vertex Pharmaceuticals (VRTX) for an upfront payment of $160 mln in cash with the potential for $90 mln in future regulatory approval milestone payments, also reported earnings)
Other news:
- TGTX +66.4% (announces 'positive' topline results from its Phase 3 GENUINE clinical trial of TG-1101 plus ibrutinib)
- PTCT +14.7% (FDA has acknowledged the filing over protest of PTC's New Drug Application for Translarna)
- ADXS +9% (announces FDA acceptance of IND for personalized neoepitope immunotherapy, ADXS-NEO)
- NOVN +8.8% (provides update on SB204 development program, intends to proceed with the SB204 development program)
- SDRL +8% (modestly rebounding following last week's 37% decline)
- CXRX +6.8% (US district court awarded the co treble damages of $2.2 mln, an increase from the original damages award of $733k)
- IMGN +4.7% (files for $200 mln mixed securities shelf offering)
- RRC +3.6% (Barron's profiles positive view on Range Resources)
- XRX +3% (Barron's profiles positive view on Xerox)
- DBVT +2.7% (reports results of 'Viaskin Peanut' study suggesting lasting response and favorable safety profile)
- RRTS +2.2% (Elliott Associates Friday increased its passive stake to 7.5%)
- VRX +1.8% (completes about $1.1 bln pay down of senior secured term loans from divestitures; to seek refinancing & amendment of credit agreement)
- AMD +1% (Mubadala Development Company PJSC proposes the sale of 45 mln shares under form 144)
- UBNT +0.8% (approved $50 mln stock repurchase program)
Analyst comments:
- AA +2.1% (upgraded to Buy from Neutral at Goldman)
- NFLX +1.4% (upgraded to Buy from Neutral at UBS)
- HPQ +0.9% (upgraded to Outperform from Market Perform at Wells Fargo)